http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20140093596-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ede47b877b6df9c8d0c494cd66f45ae8 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S424-801 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-66 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate | 2013-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b01aec110baa5428e56bc3b1d146650a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3aaf6e1ebf6bca2c61898cc0bde7aed3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_228fae4b842ca6dcb7f39cfc5ad96711 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1683b870412b21aa7cf5120a987bc7c |
| publicationDate | 2014-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20140093596-A |
| titleOfInvention | RAGE protein-beta amyloid interaction inhibitor, and pharmaceutical composition for preventing or treating diseases associated with beta amyloid accumulation containing the same as an active ingredient |
| abstract | The present invention relates to a RAGE protein-beta amyloid interaction inhibitor, and a composition for preventing or treating beta amyloid accumulation-related diseases containing the same as an active ingredient. The peptide derived from the RAGE protein V-domain and the peptide, compound or antibody targeting the RAGE protein according to the present invention antagonistic to the RAGE protein may be used for the treatment of dementia caused by beta amyloid accumulation, Alzheimer's disease, Down's syndrome , Amyloid-induced amyloidosis, amyloid-light chain amyloidosis, and the like, which can be used as a pharmaceutical composition for the treatment and prophylaxis of amyotrophic lateral sclerosis, amyloid angiopathy, amyloid cardiomyopathy, cerebral amyloid angiopathy, systemic amyloid disease, AA amyloid- In addition, the RAGE protein and beta amyloid interaction sites identified in the present invention can be usefully used for screening RAGE protein-beta amyloid interaction inhibitors. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11197908-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109476702-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109476702-B |
| priorityDate | 2013-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 435.